

Special Issue

Advances in Translational Ovarian Cancer Research

Message from the Guest Editor

Ovarian cancer is the leading cause of death among female malignancies, and despite advances in targeted therapy approaches, such as antiangiogenic therapy with bevacizumab or the administration of PARP inhibitors, patients with advanced ovarian cancer still face a poor overall prognosis. Therefore, innovative approaches for the diagnosis and personalized treatment of ovarian cancer are urgently needed in order to improve the patient outcome, which is why we are pleased to invite you to submit a manuscript on the current translational research on ovarian cancer. Our Special Issue shall cover the latest research on ovarian cancer, welcoming original articles and reviews with clinical translational implication, research areas including (but not limited to) the following:

- Novel concept for predictive and prognostic biomarkers of potential clinical significance;
- Identification of molecular targets, especially for platinum-resistant or PARPi-resistant ovarian cancer;
- Clinical studies with innovative treatment approaches for ovarian cancer.

We look forward to receiving your contributions. Dr. Jan Kuhlman

Guest Editor

Dr. Jan Kuhlmann

Department of Obstetrics and Gynecology, University of Dresden, Dresden, Germany

Deadline for manuscript submissions

closed (15 July 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/104337

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)